Gain Therapeutics, Inc. is a biotechnology company. Co. is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. Co.'s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. We show 18 historical shares outstanding datapoints in our GANX shares outstanding history coverage, used to compute GANX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing GANX market cap history over the course of time is important for investors
interested in comparing GANX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of GANX versus a peer is one thing; comparing
GANX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like GANX can fluctuate over the course of history.
With this page we aim to empower investors researching GANX by allowing them to research the GANX market cap history. |
Free GANX Email Alerts:
Video: The Importance of Market Cap
